Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $70.21 USD
Change Today +0.36 / 0.52%
Volume 779.9K
ICLR On Other Exchanges
Symbol
Exchange
Frankfurt
As of 5:20 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

icon plc (ICLR) Snapshot

Open
$69.88
Previous Close
$69.85
Day High
$70.95
Day Low
$69.19
52 Week High
03/23/15 - $72.40
52 Week Low
04/30/14 - $35.33
Market Cap
4.3B
Average Volume 10 Days
373.9K
EPS TTM
$2.80
Shares Outstanding
61.6M
EX-Date
--
P/E TM
25.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for ICON PLC (ICLR)

icon plc (ICLR) Related Businessweek News

No Related Businessweek News Found

icon plc (ICLR) Details

ICON Public Limited Company, a contract research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It develops, manages, and analyzes programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. The company also offers clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics, and laboratory services. Its clinical development services include investigator recruitment, study monitoring and data collection, case report form preparation, statistical analysis, patient safety monitoring, risk-based monitoring, clinical data management, interactive response technologies, electronic patient reported outcomes, medical reporting, patient registries, outcomes research, health economics, market access and commercialization services, strategic analysis and data operations, bioanalysis, immunoassay development, pharmacokinetic and pharmacodynamic analysis, and study protocol preparation. The company’s clinical development services also comprise regulatory consulting, product development planning, strategic consulting, pricing and market access consulting, strategic resourcing, electronic endpoint adjudication, sample analyses, safety testing, microbiology, custom flow cytometry, electronic transmission of test results, biomarker development, adaptive trial design and execution, medical device trials, and healthcare communication services. ICON Public Limited Company was founded in 1990 and is headquartered in Dublin, Ireland.

10,600 Employees
Last Reported Date: 03/12/15
Founded in 1990

icon plc (ICLR) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $6.6M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: $1.8M
Chief Operating Officer
Total Annual Compensation: $3.0M
Compensation as of Fiscal Year 2014.

icon plc (ICLR) Key Developments

Icon plc Launches Firecrest eConsent

ICON plc announced Firecrest eConsent, a next-generation electronic informed consent solution that incorporates key recommendations from the FDA’s recent draft guidance on informed consent. The e-Consent solution is a component of ICON’s new informatics hub designed to enhance the engagement of patient populations in the development process. One of the critical parts to improving this engagement is improving the informed consent process. Addressing the FDA’s recommendation for a more patient centric approach to presenting clinical trial information, ICON’s Firecrest eConsent employs videos and visual aids to assist in the explanation of complex scientific concepts and medical terms found in trial protocols. These educational techniques were developed based on research by Carnegie Mellon University, and have been systematically tested, to facilitate optimal patient comprehension and information retention. Firecrest eConsent enables patients to access materials via portals or through other online channels provided by the sponsor, giving patients more time to independently review and prepare questions for the physician before subsequently consenting to participate in the trial. Conforming with the FDA’s requirement for validating that e-signatures are written by the actual patient, Firecrest eConsent uses a new proprietary method to capture, confirm, encrypt, and store biometrics for each patient’s signature. Firecrest eConsent has also been designed to be compatible with sites’ existing IT infrastructure, enabling sites to adopt the Firecrest eConsent solution quickly and efficiently.

ICON Launches New Medical Device and Diagnostics Research Group

ICON plc has launched a new medical device and diagnostics research group. The new group combines the medical and regulatory device and diagnostic expertise of Aptiv Solutions, which ICON acquired in 2014, with ICON's global clinical development and commercialisations solutions. Device and diagnostic manufacturers can now benefit from an expanded suite of services that support the full product lifecycle, including global clinical trial execution, health economics and pricing and market access solutions. The device and diagnostic development model can differ significantly from that of pharmaceutical companies, both in complexity and time to market.

ICON plc Launches Medical Device & Diagnostics Research Group; Vicki Anastasi to Lead Medical Device & Diagnostics Research Group

ICON plc announced the launch of a new Medical Device & Diagnostics Research group focused on the unique requirements of the medical device and diagnostics industry. The new group combines the medical and regulatory device and diagnostic expertise of Aptiv Solutions, which ICON acquired in 2014, with ICON's global clinical development and commercialisations solutions. Device and diagnostic manufacturers can now benefit from an expanded suite of services that support the full product lifecycle, including global clinical trial execution, health economics and pricing and market access solutions. The company's Medical Device & Diagnostics Research group will be led by Vicki Anastasi, Vice President, Medical Device & Diagnostic Research, who has over 20 years of medical device and diagnostics experience. The group is comprised of a team of dedicated project managers and clinical operations professionals as well as regulatory and strategic consultants.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICLR:US $70.21 USD +0.36

ICLR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ergomed PLC 166.50 GBp 0.00
INC Research Holdings Inc $35.31 USD +5.19
PAREXEL International Corp $70.13 USD +2.64
VirtualScopics Inc $2.79 USD -0.009
WuXi PharmaTech Cayman Inc $40.35 USD +0.73
View Industry Companies
 

Industry Analysis

ICLR

Industry Average

Valuation ICLR Industry Range
Price/Earnings 25.6x
Price/Sales 2.8x
Price/Book 4.4x
Price/Cash Flow 18.7x
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICON PLC, please visit www.iconplc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.